|
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. |
| |
|
Honoraria - Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Pierre Fabre |
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb (Inst); Roche/Genentech |
Travel, Accommodations, Expenses - Pierre Fabre; Roche |
| |
|
Honoraria - Abbott Laboratories |
Consulting or Advisory Role - Abbott Laboratories; Bristol-Myers Squibb; Merck Serono |
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst) |
Expert Testimony - Abbott Laboratories |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
| |
|
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech |
Research Funding - AstraZeneca (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Other Relationship - Roche |
| |
|
Honoraria - Bms spain; Roche |
Consulting or Advisory Role - BeiGene |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bms Spain; MSD; Roche; Roche |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Eisai; Merck; Pfizer; Roche; Takeda |
Research Funding - AstraZeneca; Merck |
| |
|
Travel, Accommodations, Expenses - Bayer; BMS; Novartis |
| |
|
Consulting or Advisory Role - Basilea; Genmab; Novartis |
Research Funding - Basilea (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Basilea; Roche/Genentech |
| |
|
Consulting or Advisory Role - Eisai (Inst); GenMab (Inst); Roche (Inst) |
Speakers' Bureau - Eisai Europe; Eisai Europe (Inst) |
Research Funding - Celgene (Inst) |
Travel, Accommodations, Expenses - Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
|
| |
|
|
Stock and Other Ownership Interests - Merck |
Travel, Accommodations, Expenses - Merck; Merck |
| |
|
Employment - Merck Sharp & Dohme |
Stock and Other Ownership Interests - Merck |
| |
|
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks |
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono |
Research Funding - Amgen (Inst); Beigene (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst) |